Overview

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals